The cell-penetrating FOXM1 N-terminus (M1-138) demonstrates potent inhibitory effects on cancer cells by targeting FOXM1 and FOXM1-interacting factor SMAD3

Abstract

Transcription factor FOXM1 is involved in stimulating cell proliferation, enhancing DNA damage repair, promoting metastasis of cancer cells, and the inhibition of FOXM1 has been shown to prevent the initiation and progression of multiple cancers and FOXM1 is considered to be an effective target for tumor therapeutic drug development. The N-terminus of FOXM1 has been found to prevent transcriptional activities of FOXM1 and to mediate the interaction between FOXM1 and SMAD3. Methods: A recombinant FOXM1 N-terminal domain (1-138aa) fused with a nine arginine cell-penetrating peptide is produced with an E. coli expression system and named as M1-138. The effects of M1-138 on the proliferation, migration, and tumorigenic ability of cancer cells are analyzed in vitro with cell counting, transwell assays, and colony formation assays. Electrophoretic mobility shift assays (EMSAs) and Luciferase activity assays are used to test the DNA binding ability and transcriptional activity of transcription factors. The levels of mRNAs and proteins are measured by quantitative-PCR, Western blotting or Immunohistochemistry. The interactions among proteins are analyzed with Pull-down and Co-immunoprecipitation (Co-IP) assays. The nude mouse engrafted tumor models are used to test the inhibitory effects of M1-138 in vivo . Results: M1-138 diminishes the proliferation and migration abilities of cancer cells through binding to FOXM1 and FOXM1-interacting factor SMAD3, and consequently attenuating FOXM1 transcriptional activities from both direct and indirect FOXM1-promoter binding mechanisms and interfering with the interaction between FOXM1 and SMAD3. Treatment of M1-138 prevents tumorigenicity of cancer cells and inhibits tumor growth in nude mouse xenograft models with no obvious signs of toxicity. Conclusion: M1-138 is a promising drug candidate for the development of anti-cancer therapeutics targeting FOXM1 and SMAD3.

Parallel Automated Flow Synthesis of Covalent Protein Complexes That Can Inhibit MYC-Driven Transcription

“…The DNA binding regions of several transcription factors often are polycationic and α-helical, two traits of cell-penetrating peptides . Indeed, several transcription factor proteins were independently shown to be intrinsically cell-penetrating, − including Soucek’s discovery regarding Omomyc . Our group recently reported the synergistic effect of multiple cell-penetrating moieties combined in one sequence .…”

The role of cell‐penetrating peptides in potential anti‐cancer therapy

“…Zhang et al. fused a CPP‐R9 with a domain of FOXM1 and expressed the chimeric structure in bacteria successfully, demonstrating that the complex R9‐FOXM1 can inhibit the tumorigenic ability of cancer cells and tumour growth in nude mouse xenograft tumour models 120 …”

Status update in the use of cell-penetrating peptides for the delivery of macromolecular therapeutics

“…Accordingly, they fused the R9 CPP with a domain from FOXM1 and recombinantly expressed such chimeric construct in a bacterial expression system. In the end, their protein-CPP anti-cancer drug inhibited the tumorigenic ability of cancer cells and tumor growth in nude mouse xenograft models [28]. According to recent reports, another intracellular protein targeting strategy deserves attention.…”